期刊
JOURNAL OF ADVANCED RESEARCH
卷 21, 期 -, 页码 169-176出版社
ELSEVIER
DOI: 10.1016/j.jare.2019.10.005
关键词
Vancomycin-resistant Staphylococcus aureus; Treatment; Vancomycin; vanA cluster
资金
- Department of Science and Technology of Sichuan province [2019YJ0693]
- Southwest Medical University-Traditional Medicine Hospital Affiliated to Southwest Medical University [2018XYLH-017]
- National Natural Science Foundation of China [81672071, 81471993]
The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments. (C) 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据